Role of fibroblast growth factor 23 in health and in chronic kidney disease

Schiavi, 2004, The phosphatonin pathway: new insights in phosphate homeostasis, Kidney Int, 65, 1, 10.1111/j.1523-1755.2004.00355.x

2000, Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23., Nat Genet, 26, 345, 10.1038/81664

Yamashita, 2000, Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain, Biochem Biophys Res Commun, 277, 494, 10.1006/bbrc.2000.3696

Shimada, 2001, Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia, Proc Natl Acad Sci U S A, 98, 6500, 10.1073/pnas.101545198

Brame, 2004, Renal phosphate wasting disorders: clinical features and pathogenesis, Semin Nephrol, 24, 39, 10.1053/j.semnephrol.2003.08.016

Yamazaki, 2002, Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia, J Clin Endocrinol Metab, 87, 4957, 10.1210/jc.2002-021105

Jonsson, 2003, Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia, N Engl J Med, 348, 1656, 10.1056/NEJMoa020881

1995, A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets., Nat Genet, 11, 130, 10.1038/ng1095-130

Bowe, 2001, FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate, Biochem Biophys Res Commun, 284, 977, 10.1006/bbrc.2001.5084

Guo, 2001, Analysis of recombinant Phex: an endopeptidase in search of a substrate, Am J Physiol Endocrinol Metab, 281, E837, 10.1152/ajpendo.2001.281.4.E837

Kiu, 2003, Regulation of FGF23 expression but not degradation by phex, J Biol Chem, 278, 37419, 10.1074/jbc.M304544200

Benet-Pages, 2004, FGF23 is processed by proprotein convertases but not by PHEX, Bone, 35, 455, 10.1016/j.bone.2004.04.002

Shimada, 2001, Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo, Endocrinology, 143, 3179, 10.1210/endo.143.8.8795

White, 2001, Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23, Kidney Int, 60, 2079, 10.1046/j.1523-1755.2001.00064.x

Bai, 2003, The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency, J Biol Chem, 278, 9843, 10.1074/jbc.M210490200

De Beur, 2002, Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism, J Bone Miner Res, 17, 1102, 10.1359/jbmr.2002.17.6.1102

Takeuchi, 2004, Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia, J Clin Endocrinol Metab, 89, 3979, 10.1210/jc.2004-0406

Riminucci, 2003, FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting, J Clin Invest, 112, 683, 10.1172/JCI18399

White, 2005, Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation, Am J Hum Genet, 76, 361, 10.1086/427956

Benet-Pages, 2005, An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia, Hum Mol Genet, 14, 385, 10.1093/hmg/ddi034

Hoffman, 2005, Elevated fibroblast growth factor-23 in hypophsophatemic linear nevus sebaceous syndrome, Am J Med Genet A, 134, 233, 10.1002/ajmg.a.30599

Shimada, 2004, FGF-23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis, J Bone Mineral Res, 19, 429, 10.1359/JBMR.0301264

Shimada, 2004, FGF-23 transgenic mice demonstrate hypophostemic rickets with reduced expression of sodium phosphate cotransporter type IIa, Biochem Biophys Res Commun, 314, 409, 10.1016/j.bbrc.2003.12.102

Larsson, 2004, Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha (I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis, Endocrinology, 145, 3087, 10.1210/en.2003-1768

Bai, 2004, Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) deliniate a putative role for parathyroid hormone in renal phosphate wasting disorders, Endocrinology, 145, 5269, 10.1210/en.2004-0233

Shimada, 2004, Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism, J Clin Invest, 113, 561, 10.1172/JCI200419081

Sitara, 2004, Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice, Matrix Biol, 23, 421, 10.1016/j.matbio.2004.09.007

Murer, 2003, Regulation of Na/Pi transporter in the proximal tubule, Annu Rev Physiol, 65, 531, 10.1146/annurev.physiol.65.042902.092424

Segawa, 2003, Effect of hydrolysis-resistant FGF-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter, Pflugers Arch, 446, 585, 10.1007/s00424-003-1084-1

Saito, 2003, Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production, J Biol Chem, 24, 2206, 10.1074/jbc.M207872200

Segawa, 2004, Intestinal Na-Pi cotransporter adaptation to dietary Pi content in vitamin D receptor null mice, Am J Physiol Renal Physiol, 287, F39, 10.1152/ajprenal.00375.2003

Cancilla, 2001, Fibroblast growth factor receptors and their ligands in the adult rat kidney, Kidney Int, 60, 147, 10.1046/j.1523-1755.2001.00781.x

Yamashita, 2002, Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway, J Biol Chem, 277, 28265, 10.1074/jbc.M202527200

Gupta, 2004, FGF-23 is elevated by chronic hyperphosphatemia, J Clin Endocrinol Metab, 89, 4489, 10.1210/jc.2004-0724

Weber, 2003, Serum FGF23 levels in normal and disordered phosphorus homeostasis, J Bone Miner Res, 18, 1227, 10.1359/jbmr.2003.18.7.1227

Larsson, 2003, Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers, Kidney Int, 64, 2272, 10.1046/j.1523-1755.2003.00328.x

Ferrari, 2005, Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men, J Clin Endocrinol Metab, 90, 1519, 10.1210/jc.2004-1039

Mirams, 2004, Bone as a source of FGF23: regulation by phosphate B, one, 35, 1192

Saito, 2005, Circulating FGF23 is regulated by 1 alpha, 25-dihydroxyvitamin D3 and phosphate in vivo, J Biol Chem, 280, 2543, 10.1074/jbc.M408903200

Imanishi, 2004, FGF-23 in patients with end-stage renal disease on hemodialysis, Kidney Int, 65, 1943, 10.1111/j.1523-1755.2004.00604.x

Shigematsu, 2004, Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiency, Am J Kidney Dis, 44, 250, 10.1053/j.ajkd.2004.04.029

Hasegawa, 2003, FGF-23 plays a critical role in the development of reduced serum 1,25-dihydroxyvitamin D (1,25D) levels associated with renal insufficiency [abstract], J Am Soc Nephrol, 14, 40A

Nakanishi, 2005, Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients, Kidney Int, 67, 1171, 10.1111/j.1523-1755.2005.00184.x

Kazama, 2005, Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients, Kidney Int, 67, 1120, 10.1111/j.1523-1755.2005.00178.x

Sato, 2004, Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism, Am J Kidney Dis, 44, 481, 10.1016/S0272-6386(04)00817-0

Yamashita, 2004, Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism, Eur J Endocrinol, 151, 55, 10.1530/eje.0.1510055

Cormier, 2005, Expression of fibroblast growth factors 18 and 23 during human embryonic and fetal development, Gene Expr Patterns, 5, 569, 10.1016/j.modgep.2004.10.008